Skip to content
Search

Latest Stories

Despite US nod; EU, UK resist Covid-19 vaccine patent waiver

THE EU, Britain and Japan continued to voice doubts at the World Trade Organization (WTO) on Monday (31) about a proposed intellectual property waiver on Covid-19 products including vaccines, a Geneva trade official said.

Proposals to initiate text-based discussions on an IP waiver, rather than more general talks, gained traction at an informal meeting of the World Trade Organization's Agreement on Trade-Related Aspects of IP Rights (TRIPS) council, the official said.


"The virus has not given us a timeout to go on endlessly discussing the need for or benefit of a waiver. We must rather infuse some certainty in these uncertain times by agreeing to start text-based negotiations on the waiver proposal," India said in the statement.

The United States, China, Ukraine and New Zealand have thrown their weight behind the bid to waive certain TRIPS provisions.

The TRIPS waiver is a necessary, proportionate and temporary legal measure for removing IP barriers and paving the way for more companies to produce Covid-19 vaccines, therapeutics or diagnostics by providing them with the freedom to operate without the fear of infringement of IP rights or the threat of litigation.

"We as co-sponsors of the waiver proposal recognise that IPs are not the only barrier to augmenting manufacturing and addressing supply-side constraints. However, we do believe that IPs are the biggest barrier in addressing supply-side constraints, and thus need to be addressed on priority. The waiver is not sufficient, but rather a necessary element of a multipronged strategy," India also said in the statement.

However, some members "continued to express doubts about the convenience of starting negotiations and asked for more time" to analyse the proposal, the official said.

They included the European Union, Australia, Brazil, Britain, Japan, Norway, Singapore, South Korea, Switzerland and Taiwan.

Agreements at the WTO require the consensus backing of all 164 member states.

India and South Africa came forward with the original idea in October. They have also submitted a revised proposal, which currently has the express support of 63 WTO members.

The new text which they and other backers have circulated says the waiver should apply not only to vaccines, but to treatments, diagnostics, medical devices and protective equipment, along with the material and components needed to produce them.

It also says the waiver should last for "at least three years" from the date it takes effect, following which the WTO's General Council should determine whether it should be prolonged.

Differences on IP importance

The trade official said differences continued on the question of whether, and to what extent, IP protection was holding up the goal of beating the pandemic, and about the use and potential improvement of existing flexibilities within the TRIPS terms.

Questions were also raised on the duration and termination of the proposed waiver, the official said.

The United States said it was open to text-based talks on any proposal that could address the immediate need for increased vaccine production and distribution, the official said.

China said that as the initial proposal had been laid down in October, it was time to move to the next stage, the official added.

Pakistan, Argentina, Bangladesh, Egypt, Indonesia and Kenya were among the countries that expressed the need to start negotiations, said the official.

Meanwhile the EU said the immediate goal should be ramping up production alongside measures such as lifting export restrictions for vaccine ingredients.

Switzerland, also home to major pharmaceutical firms, said WTO members should explore ways to use the flexibilities within TRIPS rather than waiving them altogether, the trade official said.

Proponents argue the temporary removal of IP rights will boost production in developing countries and address the dramatic inequity in access.

However, that notion has long been met with fierce opposition from pharmaceutical giants and their host countries, which insisted patents were not the main roadblocks to scaling up production and warned the move could hamper innovation.

The TRIPS Council will hold a formal meeting on June 8-9.

More than 1.9 billion doses of Covid-19 vaccines have been injected in at least 213 territories around the world, according to an AFP count.

Just 0.3 percent have been administered in the 29 lowest-income countries, home to nine per cent of the world's population.

More For You

tech-grok

Musk – the world’s richest man – wants to be the greatest global influencer too: a Citizen Kane for our age. (Photo credit: Getty Images)

Why Britain must make social media lawful again

THIS must be a “tipping point” for the rule of law online, technology secretary Liz Kendall told the House of Commons earlier this week. X owner Elon Musk’s Grok AI tool helped that site’s users make sexist harassment the viral new year trend of 2026. Politicians across the world declared it was “appalling” and “unacceptable”. The challenge is to turn that declaratory rhetoric into action. Britain’s media regulator Ofcom will open a formal investigation.

The controversy has illuminated again how US billionaire businessman Musk takes a “pick and mix” approach as to which laws he thinks should apply to him and his companies. Even libertarian site owners tend to recognise some responsibility to remove child sexual abuse. But Musk was laughing about the nudification trend. He is contemptuous about laws curbing hate crime and the incitement of violence, saying they are signs Britain has a “fascist” government which must be overthrown. What is vital is that our government and regulators do not risk emulating Musk’s “pick and mix” approach to when unlawful content really matters. Ofcom states it will not “hesitate to investigate” when it suspects companies are failing in their duties “especially where there’s a risk of harm to children”. This will be a popular public priority. Ofcom must this year show parliamentarians and the public that it can find the bandwidth and capacity to insist on sites meeting all of their legal duties.

Keep ReadingShow less